Masonglory Limited - Ordinary Shares (MSGY)

HONG KONG, Aug. 06, 2026 (GLOBE NEWSWIRE) -- On July 31, 2026, Masonglory Limited (the “Company”) held the Company’s Extraordinary General Meeting (the “EGM”), amongst which a share consolidation was approved by the shareholders, whereby every eight issued and unissued shares of par value of US$0.0001 each in the share capital of the Company be consolidated into one (1) share of a par value of US$0.0008 each (the “Share Consolidation”) so that the authorized share capital of the Company shall be changed from US$50,000 divided into 500,000,000 shares of a par value of US$0.0001 each to US$50,000 divided into 62,500,000 shares of a par value of US$0.0008 each.

Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Masonglory Ltd. (NASDAQ: MSGY) resulting from allegations that Masonglory may have issued materially misleading business information to the investing public.

Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Masonglory Ltd. (NASDAQ: MSGY) resulting from allegations that Masonglory may have issued materially misleading business information to the investing public.

Hong Kong, March 17, 2026 (GLOBE NEWSWIRE) -- Masonglory Limited (the “Company” or “Masonglory”) (NASDAQ: MSGY), a Hong Kong based subcontractor providing wet trades and related ancillary services to private and public sectors, announces that it received a notification letter from The Nasdaq Stock Market LLC (“Nasdaq”) dated March 13, 2026, notifying the Company that it is not in compliance with the requirement to maintain a minimum closing bid price of $1 per share, as set forth in Nasdaq Listing Rule 5550(a)(2), because the closing bid price of the Company’s ordinary shares was below $1 per share for the last 30 consecutive business days (i.e. from January 28, 2026 to March 11, 2026). The Nasdaq Letter is only a notification of deficiency. It does not result in the immediate delisting and has no current effect on the listing or trading of the Company’s ordinary shares on the Nasdaq Capital Market at this time.